Pre-eclampsia surgery: Difference between revisions

Jump to navigation Jump to search
 
(12 intermediate revisions by 3 users not shown)
Line 2: Line 2:
{{Pre-eclampsia}}
{{Pre-eclampsia}}
{{CMG}} {{AE}} {{Sara.Zand}}
{{CMG}} {{AE}} {{Sara.Zand}}
==Overview==
[[Delivery]] is the mainstay of therapy for [[preeclampsia]] in the 37 weeks of [[gestation]] or occurrence of any of the following: repeated episodes of [[severe hypertension]] ([[blood pressure]]≥ 160/110 mmHg), despite maintenance treatment with 3 classes of [[antihypertensive agents]], progressive [[thrombocytopenia]], progressively abnormal [[renal]] or [[liver]] enzyme tests, [[pulmonary edema]], abnormal [[neurological features]], [[stroke]], [[myocardial infarction]], [[ HELLP syndrome]], [[eclampsia]], suspected acute [[placental abruption]] or [[vaginal bleeding]] in the absence of [[placenta previa]], abnormal fetal testing, [[ fetal death]], fetus without expectation for survival at the time of maternal diagnosis (lethal anomaly, extreme [[prematurity]]), or persistent reversed end-diastolic flow in the [[umbilical artery]].
== Delivery ==
== Delivery ==
[[Delivery]] is the mainstay of therapy for [[preeclampsia]] in the 37 weeks of [[gestation]] or occurrence any of the following:<ref>{{cite journal|title=Gestational Hypertension and Preeclampsia|journal=Obstetrics & Gynecology|volume=135|issue=6|year=2020|pages=e237–e260|issn=0029-7844|doi=10.1097/AOG.0000000000003891}}</ref>
[[Delivery]] is the mainstay of therapy for [[preeclampsia]] in the 37 weeks of [[gestation]] or occurrence of any of the following:<ref>{{cite journal|title=Gestational Hypertension and Preeclampsia|journal=Obstetrics & Gynecology|volume=135|issue=6|year=2020|pages=e237–e260|issn=0029-7844|doi=10.1097/AOG.0000000000003891}}</ref>
:*Repeated episodes of [[severe hypertension]]([[blood pressure]]≥ 160/110 mmHg, despite maintenance treatment with 3 classes of [[antihypertensive agents]]
:*Repeated episodes of [[severe hypertension]] ([[blood pressure]]≥ 160/110 mmHg, despite maintenance treatment with 3 classes of [[antihypertensive agents]])
:*Progressive [[thrombocytopenia]]
:*Progressive [[thrombocytopenia]]
:*Progressively abnormal [[renal]] or [[liver]] enzyme tests
:*Progressively abnormal [[renal]] or [[liver]] enzyme tests
:*[[Pulmonary edema]]
:*[[Pulmonary edema]]
:*Abnormal [[ neurological features]], such as severe intractable [[ headache]], repeated [[visual scotomata]],[[ convulsions]],[[Visual disturbances]], [[motor deficit]], [[alteredsensorium]]
:*Abnormal [[ neurological features]], such as severe intractable [[ headache]], repeated [[visual scotomata]], [[ convulsions]],[[Visual disturbances]], [[motor deficit]], [[alteredsensorium]]
:*[[ Stroke]]
:*[[ Stroke]]
:*[[ Myocardial infarction]]
:*[[ Myocardial infarction]]
:*[[ HELLP syndrome]]
:*[[ HELLP syndrome]] ([[hemolysis]], elevated [[liver]] enzymes, low [[platelet]])
:*Nonreassuring [[fetal status]]
:* [[Eclampsia]]
:* Suspected acute [[placental abruption]] or [[vaginal bleeding]] in the absence of [[placenta previa]]
:*Abnormal fetal testing
:*[[ Fetal death]]
:* Fetus without expectation for survival at the time of maternal diagnosis (lethal anomaly, extreme [[prematurity]])
:* Persistent reversed end-diastolic flow in the [[umbilical artery]]


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
 
[[Category:Up-to-date]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Obstetrics]]
[[Category:Obstetrics]]
Line 22: Line 30:
[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Needs content]]
{{WH}}
{{WS}}

Latest revision as of 15:00, 8 March 2021

Pre-eclampsia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pre-eclampsia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pre-eclampsia surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pre-eclampsia surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pre-eclampsia surgery

CDC on Pre-eclampsia surgery

Pre-eclampsia surgery in the news

Blogs on Pre-eclampsia surgery

Directions to Hospitals Treating Pre-eclampsia

Risk calculators and risk factors for Pre-eclampsia surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sara Zand, M.D.[2]

Overview

Delivery is the mainstay of therapy for preeclampsia in the 37 weeks of gestation or occurrence of any of the following: repeated episodes of severe hypertension (blood pressure≥ 160/110 mmHg), despite maintenance treatment with 3 classes of antihypertensive agents, progressive thrombocytopenia, progressively abnormal renal or liver enzyme tests, pulmonary edema, abnormal neurological features, stroke, myocardial infarction, HELLP syndrome, eclampsia, suspected acute placental abruption or vaginal bleeding in the absence of placenta previa, abnormal fetal testing, fetal death, fetus without expectation for survival at the time of maternal diagnosis (lethal anomaly, extreme prematurity), or persistent reversed end-diastolic flow in the umbilical artery.

Delivery

Delivery is the mainstay of therapy for preeclampsia in the 37 weeks of gestation or occurrence of any of the following:[1]

References

  1. "Gestational Hypertension and Preeclampsia". Obstetrics & Gynecology. 135 (6): e237–e260. 2020. doi:10.1097/AOG.0000000000003891. ISSN 0029-7844.